Who are Xyntha's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kogenate (BAY14-2222), Recombinant Human Coagulation FVIII, Intravenous infusions of Xyntha, Recombinant Factor VIII (rAHF), Afstyla®, Moroctocog alfa (AF-CC).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xyntha.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Xyntha — Competitive Intelligence Brief

Xyntha (xyntha) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein therapy. Area: Rare Disease.

marketed Recombinant protein therapy Coagulation factor VIII Rare Disease Live · refreshed every 30 min

Target snapshot

Xyntha (xyntha) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Xyntha TARGET	xyntha	Pfizer	marketed	Recombinant protein therapy	Coagulation factor VIII
Kogenate (BAY14-2222)	Kogenate (BAY14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Intravenous infusions of Xyntha	Intravenous infusions of Xyntha	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Factor VIII (rAHF)	Recombinant Factor VIII (rAHF)	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation Factor VIII
Afstyla®	Afstyla®	CSL Behring	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)
Moroctocog alfa (AF-CC)	Moroctocog alfa (AF-CC)	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein therapy class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xyntha — Competitive Intelligence Brief. https://druglandscape.com/ci/xyntha. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab